Sheppard's Health-e Law cover art

Sheppard's Health-e Law

Sheppard's Health-e Law

By: with Michael Orlando and Sara Shanti
Listen for free

About this listen

 A podcast dedicated to the exciting, and sometimes explosive, interaction between technology and law in the health space, covering innovations that impact healthcare, like artificial intelligence, virtual reality and wearables. Hosted by Sheppard's Digital Health team, the Health-e Law podcast dives into the legal implications of health-tech you should know about and visits with trailblazing players in the industry.Copyright © 2026 Sheppard. All Rights Reserved. Politics & Government
Episodes
  • ViVE 2026: AI and the Future of Healthcare

    ViVE 2026: AI and the Future of Healthcare
    Apr 7 2026
    Welcome to Health-e Law, Sheppard's podcast exploring the fascinating health tech topics and trends of the day. In this episode, Sheppard partner and host Michael Orlando is joined by associate Michael Sutton to discuss their experience at ViVE 2026, the premier conference for digital health innovators and leaders. What we discuss in this episode: The current prevalence and role of AI in healthcare How limited interoperability of legacy systems hinders AI adoption How AI has changed the way data is treated Potential healthcare use cases for agentic AI Challenges when using AI in the healthcare setting Why the concept of a "Human-in-the-Loop" is particularly important in healthcare The quality metrics providers should measure when evaluating AI The factors that ultimately determine whether an AI tool succeeds or fails in healthcare settings About Michael Sutton An associate in the Corporate practice group at Sheppard's Dallas office, Michael Sutton specializes in cutting-edge and disruptive areas of practice, blending healthcare, technology and legal compliance. In particular, he focuses on HIPAA and privacy regulations, considering their relationship with technological advancements in both healthcare and consumer sectors. He is skilled in negotiations regarding data usage and ownership rights, guiding clients on marketing or integrating technological innovations while navigating emerging regulations in digital healthcare, including artificial intelligence, web tracking, information blocking, offshoring and de-identification. Michael has managed investigations, worked to resolve active breach incidents and advised clients on healthcare privacy and technology matters. He supports clients navigating HIPAA and other privacy laws to ensure their objectives are achieved within all legal and regulatory requirements. Michael also provides comprehensive regulatory services to a range of healthcare participants, including investors, managed care organizations, health plans and medical groups. In particular, he has tackled operational and contractual negotiations, licensing, compliance, and fraud considerations and conducted regulatory due diligence for transactions, including mergers and acquisitions. Michael also supports transactions involving tech companies and healthcare providers, guiding negotiations related to software and service relationships while identifying vulnerabilities in targets and devising creative solutions to address them. About Michael Orlando Michael Orlando is a partner in Sheppard's San Diego (Del Mar) office. He is team leader of the firm's Technology Transactions team, a member of the Life Sciences, Healthcare and Artificial Intelligence teams, and co-leader of the firm's Digital Health & Innovation team. Michael has more than 20 years of experience advising health technology companies, insurers, healthcare systems and providers, academic medical centers and research institutions, medical device manufacturers, pharmaceutical and wellness companies on intellectual property and business transactions in key strategic areas, including EHR systems procurement and integration, telehealth, mobile health applications, clinical decision support technologies, artificial intelligence, data use, wearable devices, remote patient monitoring, medical devices and equipment, research and collaborations, patent licenses, software licenses, joint ventures, mergers and acquisitions, revenue cycle management, and other outsourcing transactions. Michael founded a software-as-a-service company before entering private practice and completed an in-house secondment at a publicly traded biotechnology company, an experience that informs his practical and business-focused approach to client engagements. Resources: ViVE Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.
    Show More Show Less
    17 mins
  • The Future of Brain Tech With Dr. Newton Howard, Founder and CEO of ni2o

    The Future of Brain Tech With Dr. Newton Howard, Founder and CEO of ni2o
    Mar 24 2026
    Welcome to Health-e Law, Sheppard's podcast exploring the fascinating health tech topics and trends of the day. In this episode, partner and host Michael Orlando welcomes Dr. Newton Howard, founder and CEO of ni2o, to discuss KIWI, the AI-driven brain implant his company is developing. Dr. Howard also shares where he sees this technology taking healthcare in the next decade, and the privacy and ethical considerations surrounding technology with such profound implications for the human mind. What we discuss in this episode: How KIWI works and how it uses AI to treat neurological disorders. Why early detection is key to the way ni2o proposes to treat Alzheimer's disease. The impact this technology will have on brain health and healthcare in the next decade. What guardrails should be considered in deploying these technologies. The privacy risks raised by the use of brain tech. Whether these types of devices could be used to manipulate thought or memory. Key considerations for the health industry in the use of brain tech. About Dr. Newton Howard Dr. Newton Howard is the founder and CEO of ni2o, a neurotechnology company developing AI-powered brain-computer interfaces to treat debilitating neurological disorders and ultimately enhance human cognitive performance. A neuroscientist, inventor and professor, he holds advanced degrees in Mathematics and Neurosurgery from Oxford University and in Cognitive Informatics and Medical Sciences from the Sorbonne. Dr. Howard's career spans academia, the U.S. military and the private sector, with professorships at Oxford, Georgetown University and MIT, where he directed the Synthetic Intelligence Lab. His foundational scientific contributions—among them the Theory of Intention Awareness, the Fundamental Code Unit and the Brain Code—have opened new pathways in predictive intelligence and the diagnosis and treatment of neurological conditions. His research has made its way into technologies used by millions of people every day, including Wi-Fi hotspots, Google Earth and Google Translate, and he has collaborated extensively with the Department of Defense on advanced defense applications of brain science and AI. Dr. Howard also founded the Howard Brain Sciences Foundation, which funds research in brain disease and neurological treatment, and C4ADS, a data-driven think tank focused on global conflict and transnational security. About Michael Orlando Michael Orlando is a partner in Sheppard's San Diego (Del Mar) office. He is team leader of the firm's Technology Transactions team, a member of the Life Sciences, Healthcare and Artificial Intelligence teams, and co-leader of the firm's Digital Health & Innovation team. Michael has more than 20 years of experience advising health technology companies, insurers, healthcare systems and providers, academic medical centers and research institutions, medical device manufacturers, pharmaceutical and wellness companies on intellectual property and business transactions in key strategic areas, including EHR systems procurement and integration, telehealth, mobile health applications, clinical decision support technologies, artificial intelligence, data use, wearable devices, remote patient monitoring, medical devices and equipment, research and collaborations, patent licenses, software licenses, joint ventures, mergers and acquisitions, revenue cycle management, and other outsourcing transactions. Michael founded a software-as-a-service company before entering private practice and completed an in-house secondment at a publicly traded biotechnology company, an experience that informs his practical and business-focused approach to client engagements. Resources: ni2o Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.
    Show More Show Less
    14 mins
  • J.P. Morgan Healthcare 2026 and Beyond: Regulation, Technology and the Future of Health Equity

    J.P. Morgan Healthcare 2026 and Beyond: Regulation, Technology and the Future of Health Equity
    Mar 5 2026
    Welcome to Health-e Law, Sheppard's podcast exploring the fascinating health tech topics and trends of the day. In this episode, partner and host Michael Orlando welcomes Adam Herbst, a partner in Sheppard's Healthcare industry team, to explore key insights from the 2026 J.P. Morgan Healthcare Conference and discuss both the pitfalls and opportunities the One Big Beautiful Bill (OBBBA) presents for the healthcare sector. What we discuss in this episode: What does the increased use of technology in healthcare mean for the aging population? What key considerations should healthcare leaders keep in mind as they adapt to OBBBA when caring for aging populations? Practical challenges providers will encounter as they seek to deploy technology solutions to address additional OBBBA restrictions. How might OBBBA change the way health systems negotiate partnerships or structure payer contracts? What are some positive outcomes that could arise with these changes? Which anticipated changes in healthcare delivery excite you most about the future of health equity? About Adam Herbst Adam Herbst is a nationally regarded authority at the intersection of healthcare law, policy and delivery, with nearly three decades of experience spanning government, health systems, nonprofits and the private sector. He advises on the full range of corporate and transactional healthcare matters including mergers, acquisitions, joint ventures and financings involving hospitals, long-term care facilities, managed care organizations and private equity funds. He is also widely recognized for his mastery of Medicaid law, financing and policy. His Medicaid work includes 1115 waivers, state-directed payments, managed care contracting, HCBS waiver design, PACE program expansion and long-term care reimbursement across multiple states. Adam regularly structures governance arrangements, negotiates complex management and administrative services agreements and guides providers and investors through multi-state regulatory approvals and compliance regimes. Clients value Adam's ability to combine inside knowledge of government with sophisticated deal experience and a genuine understanding of mission-driven care. Whether guiding a multi-state transaction, structuring a PACE or HCBS program, advising on Medicaid waivers or supporting aging and disability service organizations, he brings a holistic approach that integrates law, policy, operations and strategy, helping clients build sustainable, compliant growth models while advancing care for vulnerable populations. Before joining Sheppard, Adam served as Deputy Commissioner of the New York State Department of Health and as a special advisor to two governors, where he led major initiatives in Medicaid transformation, long-term care reform, and managed care modernization, and chaired New York's Master Plan for Aging. During the COVID-19 pandemic, he played a critical leadership role in the state's emergency response—coordinating with federal partners, standing up COVID-only nursing facilities, managing hospital surge capacity and supporting one of the largest vaccine distribution efforts in the country. His career has also included running a children's hospital, leading a major community health center and advising faith-based organizations and disability service agencies through periods of growth, transformation and financial stress. About Michael Orlando Michael Orlando is a partner in Sheppard's San Diego (Del Mar) office. He is team leader of the firm's Technology Transactions team, a member of the Life Sciences, Healthcare and Artificial Intelligence teams, and co-leader of the firm's Digital Health & Innovation team. Michael has more than 20 years of experience advising health technology companies, insurers, healthcare systems and providers, academic medical centers and research institutions, medical device manufacturers, and pharmaceutical and wellness companies on intellectual property and business transactions in key strategic areas, including EHR systems procurement and integration, telehealth, mobile health applications, clinical decision support technologies, artificial intelligence, data use, wearable devices, remote patient monitoring, and other medical devices, research and collaborations, patent licenses, software licenses, joint ventures, mergers and acquisitions, revenue cycle management, and other outsourcing transactions. Michael founded a software-as-a-service company before entering private practice and completed an in-house secondment at a publicly traded biotechnology company, an experience that informs his practical and business-focused approach to client engagements. Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It...
    Show More Show Less
    13 mins
No reviews yet